Oramed Pharmaceuticals Inc.
Extract: Bylaws Amended/Restated (Plain English Desc) from a 8-K on 09/19/2022   Download
SEC Document
SEC Filing

On September 15, 2022, the board of directors of Oramed Pharmaceuticals Inc. (the “Company”) adopted Third Amended and Restated By-laws, which became effective immediately, to among other things, permit the annual stockholder meeting to be held solely by means of remote communication, update the required vote for all matters coming before any meeting of stockholders to be decided by a majority of the votes cast by the holders of shares of stock present in person or represented by proxy at such meeting and entitled to vote on the subject matter rather than the vote of a majority of the number of shares of stock present in person or represented by proxy at such meeting and entitled to vote on the subject matter, provide that abstentions and broker non-votes shall be excluded with respect to the subject matter, set forth procedures and conditions with respect to stockholder proposals and stockholder director nominations, permit notice to be given by electronic transmission and provide that the Court of Chancery of the State of Delaware be the sole and exclusive forum for specified claims on behalf of or against the Company, its directors, officers, employees and stockholders, as applicable.